Drug Treatment

Deciphera Announces New Results from Analysis from Intrigue Study

Deciphera issued a press release today sharing the results of an exploratory analysis of data using circulating tumor DNA (ctDNA) from the INTRIGUE Phase 3 clinical study of ripretinib and announcing plans to initiate INSIGHT.

By |2023-01-04T11:40:28-05:00January 4th, 2023|News, Qinlock|

Medicare Open Enrollment Period Ends December 7th

Concerning Medicare Open Enrollment: It is especially important for GIST patients to carefully consider available plans, as one of the financial support resources that has been available through Novartis Pharmaceuticals will end on January 1, 2021.

By |2020-12-01T13:06:09-05:00December 1st, 2020|Drug Treatment, News, Patient Support|

Blueprint Medicines Announces Publication in The Lancet Oncology

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

By |2020-06-22T09:47:31-04:00June 22nd, 2020|Drug Treatment, News, Qinlock|

QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST

La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.

By |2020-06-17T11:29:18-04:00June 17th, 2020|Drug Treatment, Global, News, Qinlock|
Go to Top